Elevating serum levels of IL-6 is very common in patients with Castleman’s disease [61], and it’s well known as a key factor of the systemic inflammatory and a predictor of poor outcome of ischemic stroke [62]. This evidence concerns the gene IL6 and ischemic stroke.